神经肿瘤学中的机器学习:来自5346例患者的数据分析能否改变决策范式?
该研究系统检索2000年1月30日至2018年3月31日的PubMed和Cochrane数据库,综述机器学习在神经肿瘤学中的应用,纳入29项研究、5346例患者数据。机器学习算法用于预测2483例患者结局,敏感度78%-98%、特异度76%-95%,所有研究中准确率均高于传统方法。
要点
- 机器学习算法在神经肿瘤学中用于预测患者结局,敏感度78%-98%、特异度76%-95%。
- 所有纳入研究中,机器学习算法的准确率均高于传统方法。
- 影像分析诊断低级别与高级别胶质瘤的准确率为80%-93%,诊断高级别胶质瘤与淋巴瘤的准确率为90%。
核心结论
- 回顾性分析显示,神经肿瘤学中的机器学习算法预测患者结局比传统参数更准确。
- 若影像分析的高诊断准确率和体细胞突变检测在前瞻性研究中得到证实,组织诊断或液体活检的使用可能减少。
- 机器学习算法有望帮助指导靶向治疗、推动个体化医疗,并开辟癌症细胞信号系统的新研究领域。
研究设计与样本
- 系统文献综述,检索PubMed和Cochrane数据库,检索时间范围为2000年1月30日至2018年3月31日。
- 纳入29项研究,共5346例患者数据,按神经肿瘤学应用范围分为患者结局预测、影像分析和基因表达3类。
主要发现
- 机器学习算法用于预测2483例患者结局,敏感度范围78%-98%,特异度范围76%-95%。
- 所有研究中机器学习算法的准确率均高于传统方法。
- 影像分析机器学习算法诊断低级别与高级别胶质瘤的准确率为80%-93%,诊断高级别胶质瘤与淋巴瘤的准确率为90%。
- 7项研究使用机器学习算法分析神经肿瘤学中的基因表达。
关键数值与推荐
- 患者结局预测:机器学习算法用于2483例患者,敏感度78%-98%,特异度76%-95%。
- 影像分析:诊断低级别与高级别胶质瘤准确率80%-93%,诊断高级别胶质瘤与淋巴瘤准确率90%。
- 基因表达分析:7项研究使用机器学习算法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Machine learning (ML) is an application of artificial intelligence (AI) that gives computer systems the ability to learn data, without being explicitly programmed. Currently, ML has been successfully used for optical character recognition, spam filtering, and face recognition. The aim of the present study was to review the current applications of ML in the field of neuro-oncology. METHODS: We conducted a systematic literature review using the PubMed and Cochrane databases using a keyword search for January 30, 2000 to March 31, 2018. The data were clustered for neuro-oncology scope of ML into 3 categories: patient outcome predictors, imaging analysis, and gene expression. RESULTS: Data from 5346 patients in 29 studies were used to develop ML-based algorithms (MLBAs) in neuro-oncology. MLBAs were used to predict the outcomes for 2483 patients, with a sensitivity range of 78%-98% and specificity range of 76%-95%. In all studies, the MLBAs had greater accuracy than the conventional ones. MLBAs for image analysis showed accuracy in diagnosing low-grade versus high-grade gliomas, ranging from 80% to 93% and 90% for diagnosing high-grade glioma versus lymphoma. Seven studies used MLBAs to analyze gene expression in neuro-oncology. CONCLUSIONS: MLBAs in neuro-oncology have been shown to predict patients' outcomes more accurately than conventional parameters in a retrospective analysis. If their high diagnostic accuracy in imaging analysis and detection of somatic mutations are corroborated in prospective studies, the use of tissue diagnosis or liquid biopsy might be curtailed. Finally, MLBAs are promising to help guide targeted therapy, can lead to personalized medicine, and open areas of study in the cancer cellular signaling system, not otherwise known.
引用
- Sarkiss CA, Germano IM. Machine Learning in Neuro-Oncology: Can Data Analysis From 5346 Patients Change Decision-Making Paradigms? World Neurosurg. 2019. PMID: 30684706. doi:10.1016/j.wneu.2019.01.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。